鍗潗绠€浠�<\/strong><\/p> \n

鍗潗鍦ㄤ腑鍥借剳鍋ュ悍棰嗗煙鑰曡€樹簩鍗佸骞达紝涓€鐩寸鎵垮叧蹇冧汉绫诲仴搴凤紙human health care锛夌殑浼佷笟浣垮懡锛屽缁堟敮鎸�"鑴戝仴搴疯鍔�"鎵€鎻愬嚭鐨勫悇椤逛富寮犲拰鎺柦锛屽苟绉瀬鍙備笌AD绉戞櫘鎵嬪唽绉戞櫘瀹ｄ紶銆傚叧娉ㄨ蹇嗗仴搴凤紝鎻愬€℃棭绛涖€佹棭璇娿€佹棭娌伙紝涓嶄粎鏄叕鍙哥殑璐ｄ换锛屼篃鏄綔涓虹ぞ浼氭垚鍛樼殑璐ｄ换銆�<\/p> \n

^{[1] 涓浗鐥村憜涓庤鐭ラ殰纰嶆寚鍗楀啓浣滅粍,涓浗鍖诲笀鍗忎細绁炵粡鍐呯鍖诲笀鍒嗕細璁ょ煡闅滅鐤剧梾涓撲笟濮斿憳浼�.2018涓浗鐥村憜涓庤鐭ラ殰纰嶈瘖娌绘寚鍗�(涓€):鐥村憜鍙婂叾鍒嗙被璇婃柇鏍囧噯.涓崕鍖诲鏉傚織.2018;98(13):965-970
<\/sup>[2] Jia L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China<\/span>: a cross鈥憇ectional study. Lancet Public Health. 2020;5(12): e661鈥慹671
<\/sup>[3] Jia J, et al.Alzheimers Dement. 2018 Apr;14(4):483 491.
<\/sup>[4] Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci. 2018;11(2):147-152
<\/sup>[5] Michael C. Irizarry<\/span>, AAIC 2023 presentation"Lecanemab : Amyloid Reduction and Evidence of Downstream Biomarker Modification".
<\/sup>[6] lecanemab-irmb injection (LEQEMBI®<\/sup>), FDA label锛� 202307锛�
<\/sup>[7] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease[J]. N Engl J Med,  2023, 388(1):9-21
<\/sup>[8] Keith Johnson<\/span>. CTAD 2023 presentation"Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker".<\/sup><\/p> \n}

 <\/p> \n